AMGN - アムジェン (Amgen Inc.) アムジェン

 AMGNのチャート


 AMGNの企業情報

symbol AMGN
会社名 Amgen In (アムジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アムジェン(Amgen Inc.)はバイオテクノロジー会社である。同社は多様なヒト治療法を発見・開発・製造・提供する。同社はヒト治療事業を運営する。同社の製品ポートフォリオはNeulasta(ペグフィルグラスチム)、Aranesp(ダルベポエチンアルファ)・EPOGEN(エポエチンアルファ)等の赤血球産生促進剤(ESAs)、Sensipar/Mimpara(シナカルセット)、XGEVA(デノスマブ)、Prolia(デノスマブ)及びNEUPOGEN(フィルグラスチム)、並びにKYPROLIS(カルミゾミブ)、Vectibix(パニツムマブ)、Nplate(ロムリプスチム)、Repatha(エボロクマブ)、BLINCYTO(ブリナトモマブ)、IMLYGIC(タルミモジュラーラパーパープ)、Corlanor(イバブラジン)など他の市販製品を含む。同社は腫瘍/血液学、心臓血管疾患および神経科学の分野における重篤な疾患の治療のためのヒト治療法を提供し、反復性片頭痛治療用Erenumab、骨髄異形成症候群治療用Aranesp、急性リンパ芽球性白血病治療用BLINCYTOおよび転移性メラノーマ治療用IMLYGICを含むフェーズⅢの製品候補を提供する。   アムジェンはバイオ医薬品メ―カ―で、高度な細胞生物学と分子生物学に基づく治療薬の開発、製造、販売を展開する。特にがん、腎臓病、炎症、腫瘍学の分野での治療薬の開発に注力、製品は診療所、透析センタ―、病院に販売される。主要製品は、がん化学療法中の患者や透析患者向けの貧血症治療剤「アラネスプ」、白血球減少症治療剤「ニュ―ラスタ」など。  Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
本社所在地 One Amgen Center Drive Thousand Oaks CA 91320-1799 USA
代表者氏名 Robert A. Bradway ロバート・A・ブラッドウェイ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 805-447-1000
設立年月日 29312
市場名 NASDAQ National Market System
ipoyear 1983年
従業員数 20800人
url www.amgen.com
nasdaq_url https://www.nasdaq.com/symbol/amgn
adr_tso
EBITDA EBITDA(百万ドル) 12110
終値(lastsale) 205.72
時価総額(marketcap) 133156809623.24
時価総額 時価総額(百万ドル) 133338
売上高 売上高(百万ドル) 23188
企業価値(EV) 企業価値(EV)(百万ドル) 138440
当期純利益 当期純利益(百万ドル) 8464
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Amgen Inc. revenues increased 3% to $11.61B. Net income increased 9% to $4.61B. Revenues reflect Rest of the World segment increase of 9% to $2.51B Other segment increase of 18% to $591M. Net income benefited from Other decrease from $50M (expense) to $22M (income) Foreign currency contracts increase from $14M to $33M (income). Dividend per share increased from $2.30 to $2.64.

 AMGNのテクニカル分析


 AMGNのニュース

   Amgen To Present At The 18th Annual Morgan Stanley Global Healthcare Conference  2020/09/11 20:00:00 PR Newswire
THOUSAND OAKS, Calif., Sept. 11, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 18th Annual Virtual Global Healthcare Conference at 11:45 a.m. ET on Wednesday, Sept. 16, 2020. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the…
   Nike, Amgen Inc. share gains lead Dow's 118-point jump  2020/09/11 13:45:00 MarketWatch
The Dow Jones Industrial Average is up Friday morning with shares of Nike and Amgen Inc. delivering the strongest returns for the index. Shares of Nike and…
   Amgen Inc. (AMGN) Presents at Citi 15th Annual Biopharma Conference (Transcript)  2020/09/10 23:26:04 Seeking Alpha
Amgen Inc. (NASDAQ:AMGN) Citi 15th Annual Biopharma Conference Call September 10, 2020 02:25 PM ET Company Participants Murdo Gordon - EVP, Global Commercial Operations Peter Griffith - CFO Arvind Sood - Head, IR Conference Call Participants Mohit Bansal - Citi Presentation Mohit Bansal Great.
   Worldwide Cancer Vaccines Industry to 2027 - Featuring Advaxis, Amgen & Dynavax Technologies Among Others  2020/09/08 15:45:00 PR Newswire
DUBLIN, Sept. 8, 2020 /PRNewswire/ -- The "Cancer Vaccines Market by Technology, Type, Indication and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global cancer vaccines market was valued at $4,188…
   Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee  2020/09/01 05:00:00 Business Wire
ST GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020. Gregory Oakes has a proven track record of building and leading organizations across multiple therapeutic areas and geographies and has extensive launch and US Market Access experience. He joins from Amgen where he served as Corporate Vice President, Global Integration L
   Amgen To Present At The 18th Annual Morgan Stanley Global Healthcare Conference  2020/09/11 20:00:00 PR Newswire
THOUSAND OAKS, Calif., Sept. 11, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 18th Annual Virtual Global Healthcare Conference at 11:45 a.m. ET on Wednesday, Sept. 16, 2020. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the…
   Nike, Amgen Inc. share gains lead Dow's 118-point jump  2020/09/11 13:45:00 MarketWatch
The Dow Jones Industrial Average is up Friday morning with shares of Nike and Amgen Inc. delivering the strongest returns for the index. Shares of Nike and…
   Amgen Inc. (AMGN) Presents at Citi 15th Annual Biopharma Conference (Transcript)  2020/09/10 23:26:04 Seeking Alpha
Amgen Inc. (NASDAQ:AMGN) Citi 15th Annual Biopharma Conference Call September 10, 2020 02:25 PM ET Company Participants Murdo Gordon - EVP, Global Commercial Operations Peter Griffith - CFO Arvind Sood - Head, IR Conference Call Participants Mohit Bansal - Citi Presentation Mohit Bansal Great.
   Worldwide Cancer Vaccines Industry to 2027 - Featuring Advaxis, Amgen & Dynavax Technologies Among Others  2020/09/08 15:45:00 PR Newswire
DUBLIN, Sept. 8, 2020 /PRNewswire/ -- The "Cancer Vaccines Market by Technology, Type, Indication and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global cancer vaccines market was valued at $4,188…
   Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee  2020/09/01 05:00:00 Business Wire
ST GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020. Gregory Oakes has a proven track record of building and leading organizations across multiple therapeutic areas and geographies and has extensive launch and US Market Access experience. He joins from Amgen where he served as Corporate Vice President, Global Integration L
   Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee  2020/09/01 05:00:00 Business Wire
ST GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020. Gregory Oakes has a proven track record of building and leading organizations across multiple therapeutic areas and geographies and has extensive launch and US Market Access experience. He joins from Amgen where he served as Corporate Vice President, Global Integration L
   US stocks end mixed, wrapping up best August in decades  2020/09/01 03:36:40 Sify.com
New York: US stocks finished mixed on Monday as Wall Street wrapped up its best August in more than 30 years. The Dow Jones Industrial Average slid 223.82 points, or 0.78 per cent, to 28,430.05. The S&P 500 was down 7.70 points, or 0.22 per cent, to 3,500.31. The Nasdaq Composite Index rose 79.82 points, or 0.68 per cent, to 11,775.46, Xinhua reported. Seven of the 11 primary S&P 500 sectors closed lower, with energy down 2.2 per cent, leading the laggards. Technology climbed 0.36, the best-performing group. Meanwhile, US-listed Chinese companies traded mostly lower, with eight of the top 10 stocks by weight in the S&P US Listed China 50 index ending the day on a downbeat note. For the month, the Dow gained 7.6 per cent, its biggest August gain since 1984. The S&P 500 notched a 7 per cent monthly rise, marking its best August performance since 1986. The tech-heavy Nasdaq surged 9.6 per cent month to date. The 30-stock index kicked off the week with a shift as three of its long-standing members, Exxon Mobil, Raytheon Technologies and Pfizer, were replaced by cloud services provider Salesforce, industrial conglomerate Honeywell and biotech firm Amgen at Monday's open.
   Stock Market Today: Nasdaq Sizzles Again, New-Look Dow Drags  2020/08/31 20:53:00 Kiplinger Washington Editors
The stock market closed out August with a familiar theme from the past few months: The Nasdaq Composite surging ahead while the Dow Jones Industrial Average's blue-chips fail to keep up. The Nasdaq, which jumped 0.7% to a record-high 11,775.46, was helped by two of the highest-profile stocks of the day: Apple ( AAPL , +3.4%) and Tesla ( TSLA , +12.6%), which both started trading on a split-adjusted basis Monday. SEE MORE 13 Best Vanguard Funds for the Next Bull Market Apple split its shares 4-for-1 , while Tesla executed a 5-for-1 split , making their shares far more accessible to "mom 'n' pop" investors. Tesla's stock, in particular, is a difficult one for analysts to peg. Consider Wedbush, which updated its price target and outlook on Tesla to account for the stock split. While its 12-month price target is $380 (a 31% decline from here), it has a $700 bull-case scenario that has TSLA shares climbing another 40% from here. "We believe the stock split decision was a smart move by Tesla and its Board given the parabolic move in shares over the past six months … and likely other larger tech stalwarts will follow this same path over the coming months in our opinion," writes Wedbush analyst Daniel Ives, who points out "any regulatory and/or production issues out of Gigafactory 3 would be a clear negative growth catalyst for the name." The Dow, meanwhile, slumped 0.8% to 28,430.
   Apple loses clout in Dow post share division; Tesla flies high post split  2020/08/31 16:48:26 Economic Times India
The Dow also welcomed three new components on Monday -- Honeywell, Salesforce and Amgen to replace to ExxonMobil, Pfizer and Raytheon, giving technology a bigger clout on the index and lessening that of energy.
   What Honeywell, Salesforce, Amgen Mean for the Dow  2020/08/31 16:41:17 The Street
Here's what the new Dow components mean for the Dow.

 関連キーワード  (医薬品 米国株 アムジェン AMGN Amgen Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)